Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kenmotsu, Hirotsugu ^a   Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Isaka, Mitsuhiro ^a   Takahashi, Toshiaki ^a   Taira, Tetsuhiko ^a   Ono, Akira ^a   Maniwa, Tomohiro ^a   Takahashi, Shoji ^a   Mori, Keita ^a   Endo, Masahiro ^a   Abe, Masato ^a   Hayashi, Isamu ^a   Nakajima, Takashi ^a   Ohde, Yasuhisa ^a   Yamamoto, Nobuyuki ^a,b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenosquamos carcinoma; Driver mutation; FGFR1 copy number gain; Genetic profiling; Lung cancer; PIK3CA mutation; Squamous cell carcinoma

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; AKT1 GENE; ARTICLE; BRAF GENE; CAPILLARY ELECTROPHORESIS; DDR2 GENE; EGFR GENE; EML4 ALK GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; FUSION GENE; GENE; GENE DOSAGE; GENE MUTATION; GENE TRANSLOCATION; GENETIC VARIATION; GENOTYPE; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); KRAS GENE; MAJOR CLINICAL STUDY; MALE; MEK1 GENE; MET GENE; NRAS GENE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PTEN GENE; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SQUAMOUS CELL LUNG CARCINOMA; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER GRADING; CANCER STAGING; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENETICS; GENOTYPING TECHNIQUE; HEALTH CARE FACILITY; JAPAN; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL SPECIMEN BANKS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENOTYPING TECHNIQUES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84925246323     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-786     Document Type: Article

References (31)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano S, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito S, Toyooka S, Nakagawa K, Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
8. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(7417):519-525.
9. Paik PK, Hasanovic A, Wang L, Rekhtman N, Ladanyi M, Kris MG: Multiplex testing for driver mutations in squamous cell carcinomas of the lung. ASCO Meeting Abstracts 2012, 30(15_suppl):7505.
10. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Cho S, Kim YC, Ahn JS, Ahn MJ, et al.: Integrative and comparative genomic analysis of lung squamous cell carcinomas in East asian patients. J Clin Oncol 2014, 32(2):121-128.
11. Dearden S, Stevens J, Wu YL, Blowers D: Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013, 24(9):2371-2376.
12. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
13. Oxnard GR, Binder A, Janne PA: New targetable oncogenes in non-smallcell lung cancer. J Clin Oncol 2013, 31(8):1097-1104.
14. Gadgeel SM: New targets in non-small cell lung cancer. Curr Oncol Rep 2013, 15(4):411-423.
15. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W: A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011, 13(1):74-84.
16. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N: Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective single-institute study. Cancer 2014, 120(10):1471-1481.
17. Ross JS, Cronin M: Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011, 136(4):527-539.
18. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001, 31(2-3):139-148.
19. Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E: Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J Surg Res 2010, 160(2):179-183.
20. Onozato W, Yamashita K, Kuba T, Katoh H, Nakamura T, Sato T, Ihara A, Okayasu I, Watanabe M: Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. J Surg Oncol 2011, 103(1):25-33.
21. Ueno T, Toyooka S, Suda K, Soh J, Yatabe Y, Miyoshi S, Matsuo K, Mitsudomi T: Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer 2012, 78(3):207-211.
22. Liu D, Hou P, Liu Z, Wu G, Xing M: Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009, 69(18):7311-7319.
23. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68(17):6913-6921.
24. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y: PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54(2):209-215.
25. Koh Y, Kenmotsu H, Serizawa M, Isaka M, Mori K, Imai H, Akamatsu H, Ono A, Naito T, Taira T, Murakami H, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N: Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing. ASCO Meeting Abstracts 2013, 31(15_suppl):7572.
26. Brooks AN, Kilgour E, Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18(7):1855-1862.
27. Drilon A, Rekhtman N, Ladanyi M, Paik P: Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012, 13(10):e418-e426.
28. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ: FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012, 7(12):1775-1780.
29. Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y: Increased FGFR1 copy number in lung squamous cell carcinomas. Mol Med Rep 2012, 5(3):725-728.
30. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC: Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013, 31(6):731-737.
31. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.